JP2014515035A - ストレプトコッカス・ニューモニエに対するワクチン - Google Patents

ストレプトコッカス・ニューモニエに対するワクチン Download PDF

Info

Publication number
JP2014515035A
JP2014515035A JP2014510771A JP2014510771A JP2014515035A JP 2014515035 A JP2014515035 A JP 2014515035A JP 2014510771 A JP2014510771 A JP 2014510771A JP 2014510771 A JP2014510771 A JP 2014510771A JP 2014515035 A JP2014515035 A JP 2014515035A
Authority
JP
Japan
Prior art keywords
immunogenic composition
composition according
phtd
mpl
pneumolysin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014510771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515035A5 (enExample
Inventor
ドノエル，フィリップ
プールマン，ジャン
ヴェルラント，ヴィンセント
ワッレマック，ユーグ
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1108256.7A external-priority patent/GB201108256D0/en
Priority claimed from GBGB1121647.0A external-priority patent/GB201121647D0/en
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2014515035A publication Critical patent/JP2014515035A/ja
Publication of JP2014515035A5 publication Critical patent/JP2014515035A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2014510771A 2011-05-17 2012-05-15 ストレプトコッカス・ニューモニエに対するワクチン Ceased JP2014515035A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1108256.7A GB201108256D0 (en) 2011-05-17 2011-05-17 Vaccine
GB1108256.7 2011-05-17
GBGB1121647.0A GB201121647D0 (en) 2011-12-16 2011-12-16 Vaccine
GB1121647.0 2011-12-16
PCT/EP2012/058987 WO2012156391A1 (en) 2011-05-17 2012-05-15 Vaccine against streptococcus pneumoniae

Publications (2)

Publication Number Publication Date
JP2014515035A true JP2014515035A (ja) 2014-06-26
JP2014515035A5 JP2014515035A5 (enExample) 2015-06-25

Family

ID=46062296

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014510771A Ceased JP2014515035A (ja) 2011-05-17 2012-05-15 ストレプトコッカス・ニューモニエに対するワクチン

Country Status (17)

Country Link
US (1) US20140072622A1 (enExample)
EP (1) EP2709658A1 (enExample)
JP (1) JP2014515035A (enExample)
KR (1) KR20140033127A (enExample)
CN (1) CN103533953A (enExample)
AR (1) AR086405A1 (enExample)
AU (1) AU2012257771C1 (enExample)
BR (1) BR112013029514A2 (enExample)
CA (1) CA2834834A1 (enExample)
EA (1) EA201391456A1 (enExample)
IL (1) IL229051A0 (enExample)
MX (1) MX339058B (enExample)
SG (1) SG194733A1 (enExample)
TW (1) TW201309327A (enExample)
UY (1) UY34073A (enExample)
WO (1) WO2012156391A1 (enExample)
ZA (1) ZA201308537B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013333975A1 (en) * 2012-10-17 2015-05-07 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
US20180327436A1 (en) 2015-11-06 2018-11-15 Adjuvance Technologies, Inc. Triterpene saponin analogues
US11844829B2 (en) * 2016-12-28 2023-12-19 Zalvac Ab Microparticles from Streptococcus pneumoniae as vaccine antigens
WO2018217882A1 (en) * 2017-05-23 2018-11-29 EMULATE, Inc. Advanced pulmonary models
US11324821B2 (en) * 2017-10-16 2022-05-10 Adjuvance Technologies, Inc. Triterpene saponin analogues
US20240180940A1 (en) * 2021-05-27 2024-06-06 Revelation Biosciences, Inc. Mpla compositions and methods of use
CN116212012A (zh) * 2021-12-02 2023-06-06 上海泽润生物科技有限公司 复合佐剂以及包含它的疫苗制剂
WO2025229688A1 (en) * 2024-05-03 2025-11-06 Kumar Samal Shailesh Method for producing anti-phosphorylcholine antibodies and vaccine composition thereof
CN118702827B (zh) * 2024-08-27 2025-03-07 南京澄实生物医药科技有限公司 一种预防肺炎链球菌感染的融合蛋白及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508417A (ja) * 2000-09-15 2004-03-18 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム ワクチン
JP2009519309A (ja) * 2005-12-13 2009-05-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンアジュバントを含むワクチン組成物
JP2009520759A (ja) * 2005-12-22 2009-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎球菌多糖類コンジュゲートワクチン

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
RU2121481C1 (ru) 1988-12-16 1998-11-10 Де Стат Дер Недерланден Вертегенвордигд Дор де Министр Ван Велзейн, Волксгезондхейд эн Кюлтюр Модифицированный пневмолизин, рекомбинантная плазмида, способ получения модифицированного пневмолизина, вакцина
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
CA2104014C (en) 1991-02-15 2000-05-02 David E. Briles Structural gene of pneumococcal protein
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
SK117395A3 (en) 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
ATE195740T1 (de) 1993-11-17 2000-09-15 Om Pharma Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
EP0912608B1 (en) 1996-05-01 2006-04-19 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
ZA975326B (en) 1996-06-18 1998-01-14 Alza Corp Device and method for enhancing transdermal flux of agents being delivered or sampled.
EP0956289A4 (en) 1996-08-16 2004-10-13 Smithkline Beecham Corp NOVEL PROKARYOTA POLYNUCLEOTIDES AND POLYPEPTIDES AND USES THEREOF
ATE348887T1 (de) 1996-10-31 2007-01-15 Human Genome Sciences Inc Streptococcus pneumoniae antigene und impfstoffe
AU5355398A (en) 1996-11-12 1998-06-03 Regents Of The University Of Minnesota C3 binding protein of (streptococcus pneumoniae)
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
WO1998028037A1 (en) 1996-12-20 1998-07-02 Alza Corporation Device and method for enhancing transdermal agent flux
DE19708537A1 (de) 1997-03-03 1998-09-10 Biotechnolog Forschung Gmbh Neues Oberflächenprotein (SpsA-Protein) von Streptococcus pneumoniae etc.
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
KR20010024299A (ko) 1997-09-24 2001-03-26 리전츠 오브 더 유니버스티 오브 미네소타 스트렙토코쿠스 뉴모니애로부터의 사람 보체 ｃ3 분해단백질분해효소
EP1035867A1 (en) 1997-12-02 2000-09-20 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
TR200003498T2 (tr) 1998-04-07 2001-10-22 St. Jude Children's Research Hospital Amino asit sekansından oluşan bir polipetit, bunun aşıları ve kullanımları
DE69942176D1 (de) 1998-04-07 2010-05-06 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
JP2002516251A (ja) 1998-04-23 2002-06-04 ユーエイビー リサーチ ファンデーション 肺炎球菌表面プロテインＣ（ＰｓｐＣ）のエピトープ領域およびその菌株選択、ならびにそのための使用法
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
PL195764B1 (pl) 1998-06-30 2007-10-31 Om Pharma Pseudodipeptydy N-acylowe, sposoby wytwarzania pseudodipeptydów N-acylowych i kompozycje farmaceutyczne
KR20010089280A (ko) 1998-09-24 2001-09-29 리전츠 오브 더 유니버스티 오브 미네소타 스트렙토코쿠스 뉴모니애로부터의 인간 보체 ｃ3 분해폴리펩티드
WO2000030299A1 (en) 1998-11-17 2000-05-25 Schlumberger Technology Corporation Transmitting information over a communication link
AU2027400A (en) 1998-11-19 2000-06-05 St. Jude Children's Research Hospital Identification and characterization of novel pneumococcal choline binding proteins, cbpg and cbpd, and diagnostic and therapeutic uses thereof
CA2355364C (en) * 1998-12-21 2014-03-18 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
PT2261358E (pt) 1998-12-23 2014-07-30 Id Biomedical Corp Quebec Antigénios de streptococcus
JP2002542203A (ja) 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
WO2000076540A2 (en) 1999-06-10 2000-12-21 Med Immune, Inc. Streptococcus pneumoniae proteins and vaccines
FR2796291B1 (fr) 1999-07-16 2001-09-21 Cross Site Technologies Seringue sans aiguille munie d'un systeme de declenchement piezo-electrique
FR2796289B1 (fr) 1999-07-16 2001-08-10 Cross Site Technologies Seringue sans aiguille avec injecteur a elements superposes
FR2796290B1 (fr) 1999-07-16 2001-09-14 Cross Site Technologies Seringue sans aiguille fonctionnant avec un generateur d'onde de choc a travers une paroi
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2800619B1 (fr) 1999-11-05 2002-02-08 Cross Site Technologies Seringue sans aiguille avec un moyen de poussee temporairement retenu
FR2802102B1 (fr) 1999-12-08 2002-07-12 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un tube d'ejection a section constante
FR2802103B1 (fr) 1999-12-08 2003-10-03 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec entrainement du principe actif par effet tube a choc
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
FR2802820B1 (fr) 1999-12-27 2002-10-18 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par effet tube a choc, avec maintien prealable du principe actif sur le cote
FR2804329B1 (fr) 2000-02-02 2002-12-13 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un opercule contenant le principe actif
FR2804869B1 (fr) 2000-02-11 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille pour l'injection d'un liquide contenu dans une ampoule pre-remplie
FR2805749B1 (fr) 2000-03-01 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille a deux niveaux de vitesse d'injection
FR2807946B1 (fr) 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
FR2809626B1 (fr) 2000-05-30 2003-03-07 Poudres & Explosifs Ste Nale Seringue sans aiguille avec membrane d'isolation d'un ejecteur multiconduit
HU228706B1 (en) 2000-06-20 2013-05-28 Id Biomedical Corp Streptococcus antigens
FR2810554B1 (fr) 2000-06-22 2003-05-16 Poudres & Explosifs Ste Nale Seringue sans aiguille munie d'un reservoir modulable
FR2812202B1 (fr) 2000-07-28 2002-09-13 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant par mise en compression du reservoir contenant le principe actif liquide
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
AU2003291365B2 (en) 2002-11-07 2009-06-11 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
WO2004081515A2 (en) 2003-03-13 2004-09-23 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
CA2555803A1 (en) 2004-02-13 2005-08-27 Sanofi Pasteur Limited Pneumolysin derivatives
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
GB0525321D0 (en) * 2005-12-13 2006-01-18 Glaxosmithkline Biolog Sa Novel compositions
SI2068918T2 (sl) * 2006-09-26 2024-10-30 Access To Advanced Health Institute Sestavek za cepljenje, ki vsebuje sintetična pomagala
KR101595234B1 (ko) 2007-07-23 2016-02-26 사노피 파스퇴르 리미티드 면역원성 폴리펩타이드 및 단일클론 항체
BRPI0814594A2 (pt) 2007-07-26 2015-01-20 Sanofi Pasteur Ltd Composições e métodos adjuvantes de antígeno
GB0724357D0 (en) 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
ES2331863B1 (es) 2008-07-15 2010-10-27 Consejo Superior De Investigaciones Cientificas (Csic) Bacterias y productos derivados para fortalecer las defensas y reducir el riesgo de enfermedad.
EP2376526A4 (en) 2008-12-24 2013-02-27 Kingdom Of The Netherlands Represented By The Min Ister Of Health Welfare & Sport On Behalf Of The M MODIFIED STREPTOCOCCUS PNEUMONIAE PNEUMOLYSIN (PLY) POLYPEPTIDE
JP5806204B2 (ja) 2009-03-24 2015-11-10 ノバルティス アーゲー 肺炎球菌血清型１４の糖を含む組み合わせ
WO2010140119A1 (en) 2009-06-01 2010-12-09 Novartis Ag COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES
BR112012018343A2 (pt) 2009-12-22 2017-06-27 Sanofi Pasteur Ltd "composições imunogênicas"

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508417A (ja) * 2000-09-15 2004-03-18 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム ワクチン
JP2009519309A (ja) * 2005-12-13 2009-05-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンアジュバントを含むワクチン組成物
JP2009520759A (ja) * 2005-12-22 2009-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎球菌多糖類コンジュゲートワクチン

Also Published As

Publication number Publication date
MX339058B (es) 2016-05-09
SG194733A1 (en) 2013-12-30
WO2012156391A1 (en) 2012-11-22
US20140072622A1 (en) 2014-03-13
BR112013029514A2 (pt) 2019-09-24
KR20140033127A (ko) 2014-03-17
AU2012257771A1 (en) 2013-04-04
AR086405A1 (es) 2013-12-11
TW201309327A (zh) 2013-03-01
CA2834834A1 (en) 2012-11-22
UY34073A (es) 2013-01-03
EA201391456A1 (ru) 2014-05-30
EP2709658A1 (en) 2014-03-26
IL229051A0 (en) 2013-12-31
ZA201308537B (en) 2015-08-26
MX2013013444A (es) 2013-12-06
AU2012257771C1 (en) 2015-12-03
CN103533953A (zh) 2014-01-22
AU2012257771B2 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
AU2012257771B2 (en) Vaccine against Streptococcus pneumoniae
KR101268790B1 (ko) 백신
CA2900008C (en) PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
AU2010273708B2 (en) Vaccines and compositions against Streptococcus pneumoniae
KR20120034612A (ko) 황색 포도상구균에 대한 면역화를 위한 조성물
MX2010011412A (es) Vacuna.
SG192060A1 (en) Vaccines and compositions against streptococcus pneumoniae
JP2024501754A (ja) ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）感染症に対するワクチン組成物
WO2009094730A1 (en) Vaccine compositions
CN106606775A (zh) 脂质体a群链球菌疫苗
EP4482521A1 (en) A novel cationic adjuvant composition
JP2022544407A (ja) 免疫原性組成物
US20230045642A1 (en) S. aureus antigens and compositions thereof
EA049052B1 (ru) Вакцинная композиция против инфекции streptococcus pneumoniae
JP2013510188A (ja) 黄色ブドウ球菌に由来する菌血症関連抗原
WO2018091142A1 (en) Cyaa polypeptides as immune enhancer
EP3541412A1 (en) Cyaa polypeptides as immune enhancer
TW201726164A (zh) 脂質體疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170208

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170425

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20170829